Results for: CAR-T cell therapy

Lyell Immunopharma Inc. (LYEL) has acquired ImmPACT Bio USA Inc., a clinical-stage biotechnology company, for $30 million in cash and 37.5 million Lyell shares. This acquisition brings IMPT-314, a CAR T-cell therapy, to Lyell’s pipeline, but analysts are concerned about the complexities and potential distractions it introduces. Lyell is also discontinuing several programs, including LYL797 and LYL845, to focus on its most differentiated CAR T-cell therapies and the upcoming Phase 1 clinical trial of LYL119. Despite the strategic shift, analysts remain cautious about Lyell’s future due to increased competition and the uncertainty surrounding IMPT-314’s clinical benefits.

King Faisal Specialist Hospital & Research Centre (KFSHRC) will be a Platinum Sponsor at the Global Health Exhibition 2024 in Riyadh, showcasing groundbreaking healthcare advancements like robotic heart surgery, organ transplantation, and CAR-T cell production. The event provides a platform for KFSHRC to share its commitment to enhancing healthcare outcomes and solidifying its position as a leader in global healthcare.

A new case report suggests that CAR T-cell therapy, typically used for cancer treatment, may be effective in treating Stiff Person Syndrome (SPS), a rare neurological disorder characterized by painful muscle spasms. The therapy successfully reduced symptoms and improved mobility in a patient with SPS, offering hope for a new treatment option.